NCT07902713
Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response Rate (ORR)
Timeframe: From the first dose of study treatment until disease progression, initiation of new anticancer therapy, death, or the last tumor assessment, whichever occurs first (assessed up to approximately 24 months).
Secondary (6)
Disease Control Rate (DCR)
Duration of Response (DoR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Incidence of Treatment-Related Adverse Events (TRAEs)
Show 1 moreShow less
Incidence of Serious Adverse Events (SAEs)
Arms and interventions
Becotatug Vedotin + Gemcitabine + PD-1 InhibitorExperimental
Participants will receive becotatug vedotin (2.0 mg/kg intravenously on Day 1), gemcitabine (1,000 mg/m² intravenously on Days 1 and 8), and a PD-1 inhibitor (camrelizumab, 200 mg intravenously on Day 1) every 21 days for 4-6 cycles. Following combination treatment, participants will receive maintenance therapy with a PD-1 inhibitor (camrelizumab, 200 mg intravenously every 3 weeks) until disease progression or unacceptable toxicity.
Drugs: Becotatug Vedotin (MRG003), Gemcitabine (1000 mg/m2), Camrelizumab
Sites
1 site in 1 country
- Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, China